RHJA
MXCT icon

Rice Hall James & Associates’s MaxCyte MXCT Stock Holding History

Rice Hall James & Associates’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-417,846
Closed -$911K – 255
2025
Q2 		$911K Sell
417,846
-36,519
-8% -$88.4K 0.05% 203
2025
Q1 		$1.24M Buy
454,365
+190,532
+72% +$751K 0.07% 188
2024
Q4 		$1.1M Buy
+263,833
New +$997K 0.06% 203

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rice Hall James & Associates's MXCT Position: Q3 2025 in Review

Rice Hall James & Associates sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 417,846 shares — an estimated $911K sold.

Rice Hall James & Associates first reported a position in MXCT in Q4 2024 and held it in 3 quarters. The position peaked at $1.24M in Q1 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • Rice Hall James & Associates reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • Rice Hall James & Associates sold 417,846 MaxCyte shares in Q3 2025, an estimated $911K.
  • Rice Hall James & Associates first reported a position in MaxCyte in Q4 2024 and held it in 3 quarters.
  • Rice Hall James & Associates's MaxCyte position peaked at $1.24M in Q1 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on Rice Hall James & Associates's 13F filing for Q3 2025, filed 16 Oct 2025.